MarketPulse

obesity drug market

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics' Billion-Dollar Bet: Can VK2735 Compete in the Weight-Loss Gold Rush?

Viking Therapeutics' VK2735 targets the $100+ billion weight-loss market. Success could drive massive stock appreciation, but clinical and competitive risks remain substantial.
LLYVKTXbiotechregulatory approval
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials